<DOC>
	<DOCNO>NCT00363831</DOCNO>
	<brief_summary>Primary : - To evaluate efficacy capecitabine combination oxaliplatin ( XELOX ) term overall response rate ( base RECIST criterion ) patient metastatic NPC without prior chemotherapy relapse . Secondary : - To evaluate efficacy profile oxaliplatin ( XELOX ) patient metastatic NPC term time progression disease , survival time , duration response complete response rate . - To study safety tolerability regimen patient metastatic NPC .</brief_summary>
	<brief_title>Combination Capecitabine Oxaliplatin Metastatic Nasopharyngeal Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Histologically confirm poorly differentiate undifferentiated nasopharyngeal carcinoma ( WHO type II III ) distant metastasis ( ie . locoregional disease ) . Patients stage IVc disease , ie . distant metastasis presentation also eligible . Have least one measurable lesion accord RECIST irradiated . WBC count ≥ 3 x 10^9 /L neutrophil ≥ 1.5 x 10^9 /L , platelet count ≥ 100 x 10^9 /L Hb ≥ 9g/dL . Serum creatinine ≤ 1.25 ULN Be ambulatory Karnofsky Performance Status ≥ 70 % study entry . Recover prior radiotherapy prior study entry Effective contraception male female risk conception exists . Able swallow retain oral medication . Previous cytotoxic chemotherapy recurrent metastatic NPC . Previous exposure oxaliplatin and/or capecitabine . Pregnant lactating woman . Women childbearing potential either positive pregnancy test baseline . Women childbearing potential use reliable appropriate contraceptive method . ( Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential ) Sexually active male unwilling practice contraception study . Clinically significant cardiac disease ( eg . congestive heart failure , symptomatic coronary artery disease cardiac arrhythmia well controlled medication ) myocardial infarction within last 12 month . Patients history central nervous system disorder psychiatric disability judge investigator clinically significant precluding inform consent interfere compliance oral drug intake . History another malignancy within last five year except cure basal cell carcinoma skin cure carcinoma insitu uterine cervix . Abnormal blood count , AST , ALT , bilirubin and/or serum creatinine beyond limit specify inclusion criterion . Radiotherapy within 4 week treatment start prior radiotherapy indicator lesion ( ) measure study ( newly arise marker lesion previously irradiate area acceptable ) . Major surgery within 4 week start study treatment , without complete recovery . Participation investigational drug study within 4 week precede start treatment . Symptomatic peripheral neuropathy NCICTCAE grade ≥ 2 . Known allergic/hypersensitivity reaction component study treatment . Serious uncontrolled intercurrent infection . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>